Exogenous supplementation of APN or dual agonists of AdipoR1/2 may restore physiological equilibrium of IRS1/2, AKT and mTOR in colons of IBD individuals, and reduce IGF-1 endogenous desensitization, which possibly exerts a similar therapeutic effect as IGF-1 treatment. Here, IGF1 is linked to inflammatory bowel disease.